The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in recurrent implantation failure (RIF) patients with latent genital tuberculosis (LGTB), compared to no treatment and non-LGTB patients.
The prevalence of latent genital tuberculosis (LGTB) is relatively high in women with infertility and recurrent pregnancy loss. Whether preventive treatment of latent tuberculosis infection (LTBI) can improve the fertility outcome in women with recurrent implantation failure (RIF) remains to be explored. This is a prospective interventional cohort study.The main purpose of this study is to compare the fertility outcome between 1-month regimen of three times weekly rifapentine plus isoniazid and no treatment in RIF patients with LGTB and RIF patients without LGTB. The study will also assess the safety and tolerability and the efficacy of the preventive treatment regimen in prevention of the incidence of active female genital tuberculosis (FGTB). A total of 1050 participants will be recruited for screening of LGTB. The endometrial tuberculosis (TB) polymerase chain reaction (PCR) test will be employed for the diagnosis of LGTB. Eligible participants with negative TB PCR results will be assigned to the non-LGTB group, while those with positive TB PCR results will be assigned to the LGTB group. The LGTB group will be further assigned, according to their will to receive preventive treatment of tuberculosis, to one of the following groups: the LGTB treatment group and the LGTB no treatment group. The LGTB treatment group will receive the 1-month regimen of three times weekly rifapentine plus isoniazid, and the in vitro fertilization (IVF)/ intra cytoplasmic sperm injection (ICSI) cycle can be started after 1 month post the completion of the treatment regimen. Adverse events and side effects will be monitored at a 2-week interval during the preventive treatment and followed up once more at 4 weeks post the end of treatment. The LGTB no treatment group and the non-LGTB group will start the IVF/ICSI cycle directly after enrollment without taking any medication related to preventive treatment of tuberculosis. Eligible participants will be followed up until the end of an IVF/ ICSI cycle or pregnancy. Fertility outcomes of both groups will be recorded and compared. Secondary outcomes, including the incidence of adverse events, the adhesion of treatment and the incidence of LGTB and FGTB, ovarian reserve, embryo quality, history of infertility and tuberculosis will also be recorded and compared.
Study Type
INTERVENTIONAL
receive the 1-month regimen of three times weekly rifapentine (450mg po) plus isoniazid (400mg po)
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, China
Clinical pregnancy rates
Clinical pregnancy was defined as the presence of at least one gestational sac on ultrasound at 6 weeks.
Time frame: 6 weeks after completion of an IVF/ICSI cycle
Ongoing Pregnancy Rate
Ongoing pregnancy was the presence of at least one foetus with heart pulsation on ultrasound beyond 10 weeks.
Time frame: 10 weeks after completion of an IVF/ICSI cycle
Miscarriage rate
The number of miscarriages before 22 weeks divided by the number of participants with positive pregnancy test.
Time frame: 22 weeks after completion of an IVF/ICSI cycle
Implantation rate
The number of gestational sacs seen on scanning divided by the number of embryos replaced.
Time frame: 6 weeks after completion of an IVF/ICSI cycle
Incidence of LGTB
The number of participants diagnosed with LGTB devided by the number of participants screened for LGTB.
Time frame: 4 weeks after enrollment
Incidence of FGTB
The number of participants developed FGTB during treatment or follow-up devided by the number of participants in the LGTB treatment group.
Time frame: 2 years
Incidence of grade 3 or greater adverse events
The number of participants reported grade 3 or greater adverse events during treatment or follow-up devided by the number of participants in the LGTB treatment group.
Time frame: 20 weeks after preventive treatment initiated
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,050
Completion rate of preventive treatment
11 or 12 doses of the 1-month preventive treatment regimen of three times weekly rifapentine plus isoniazid taken within 16 weeks after treatment initiated will be regarded as completion of preventive treatment. The number of participants completed treatment devided by the number of participants initiated the preventive treatment.
Time frame: 20 weeks after preventive treatment initiated
Discontinuation of treatment
The number of participants discontinued treatment devided by the number of participants in the LGTB treatment group.
Time frame: 20 weeks after preventive treatment initiated
Discontinuation of treatment due to side effect of study drugs
The number of participants discontinued treatment due to side effect of study drugs devided by the number of participants in the LGTB treatment group.
Time frame: 20 weeks after preventive treatment initiated